NC-LENOVO
15.2.2024 15:01:34 CET | Business Wire | Press release
Today, Lenovo™ announced a strategic partnership with Anaconda® Inc., the leading provider of the world’s most popular artificial intelligence (AI), machine learning (ML) and data science platform, to empower Lenovo’s high performance data science workstations. The partnership will couple Lenovo’s trusted ThinkStation™ and ThinkPad™ workstation product portfolio heritage and leadership with Anaconda’s enterprise strengths for open-source leadership, security, and reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215334255/en/
Lenovo and Anaconda Announce Agreement to Accelerate AI Development and Deployment (Photo: Business Wire)
The rapidly evolving world of artificial intelligence, deep learning and generative AI is opening up new opportunities for businesses and data scientists. Much of the AI innovation taking place today is driven by open-source software and cloud-based solutions, with Python being a leading software language for AI applications. However, the data security risks associated with utilizing open-source software at an enterprise level, privacy concerns and often prohibitive cost of cloud-based AI solutions, is causing many organizations to rethink their approach to investment in AI development. With Intel®-powered Lenovo workstations architected with the latest generations of professional NVIDIA® GPUs built for large-language model fine-tuning, and the Anaconda Navigator’s ability to enable businesses to leverage open-source and AI with enhanced security, scale, and governance mechanisms in place, the partnership allows data scientists to create and deploy AI solutions with first class hardware and enterprise-grade AI software support within a more manageable investment framework.
Optimized for Intel platforms, Lenovo’s new generation of data science workstations deliver remarkable AI performance and is one of the world’s most powerful and scalable AI workstation portfolios. Planning for AI projects requires clear and thoughtful pathways to allocate the right hardware, software and skillsets to manage each stage of AI development. Lenovo workstations complement cloud-based AI solutions by acting as a bridge between local and cloud resources and aid data scientist flexibility and productivity. Lenovo’s full workstation portfolio includes highly configurable systems designed for nearly every AI workflow, industry or vertical, size and price point – all architected to drive the future of AI forward in an agile and cost-efficient way. From single CPU and GPU mobile workstations that are ideal for data input, collection and preparation, to the most powerful dual CPU and four GPU configurations for advanced AI workflows, Lenovo workstations with Anaconda Navigator offer protected “sandbox” environments to tackle the most complex AI solution development and deployment.
“With Lenovo’s trusted workstation leadership and Anaconda’s trusted leadership in open-source software support and reliability, the partnership is a perfect match,” said Rob Herman, Vice President and General Manager, Workstation and Client AI Group at Lenovo. “We’re excited to activate this partnership to aid data scientists in pushing forward the capabilities of AI with our premium workstations portfolio and Anaconda’s stellar open-source packages and repositories.”
Anaconda Navigator is available for download to use on current and future generation Lenovo Workstations.
“As artificial intelligence and machine learning models grow increasingly complex, high-performance workstations are imperative to empower data scientists with advanced capabilities,” said Chandler Vaughn, Chief Product Officer at Anaconda. “Lenovo's leadership in supplying optimized workstations, featuring robust GPUs, memory, and storage, positions them as an ideal collaborator for Anaconda and our Navigator desktop product. By jointly providing resilient hardware and trusted software tools, Lenovo and Anaconda present data scientists, AI developers, and AI engineers an unrivaled platform to freely explore emerging techniques in AI/ML. This symbiotic relationship enables organizations to push boundaries and accelerate innovations in artificial intelligence without technological constraints.”
For more information about Lenovo’s workstation portfolio, visit www.lenovo.com/workstations.
About Lenovo
Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
About Anaconda
With more than 45 million users, Anaconda is the most popular operating system for AI providing access to the foundational open-source Python packages used in modern AI, data science and machine learning through a seamless platform. We pioneered the use of Python for data science, championed its vibrant community, and continue to steward open-source projects that make tomorrow’s innovations possible. Our enterprise-grade solutions enable corporate, research, and academic institutions around the world to harness the power of open-source for competitive advantage, groundbreaking research, and a better world. To learn more visit anaconda.com or connect on Twitter or LinkedIn.
LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. Anaconda is a registered trademark owned by Anaconda, Inc. Intel is a trademark of Intel Corporation or its subsidiaries in the U.S. and/or other countries. NVIDIA is a trademark of NVIDIA Corporation. Inc. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215334255/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom